Phase 3 antibiotic, omadacycline, highly active against common bacterial pathogens in ABSSSI, RTI and UTI
by Press Release from Outbreak News Today on (#2RRYX)
New data presented today at ASM Microbe 2017 showed that Paratek Pharmaceuticals, Inc.'s Phase 3 antibiotic omadacycline is highly active against common bacterial pathogens in acute skin and skin structure infections (ABSSSI), respiratory tract infections (RTI), and the key bacterial pathogens responsible for urinary tract infections (UTI). The study evaluated the in vitro antibacterial activity ["]
The post Phase 3 antibiotic, omadacycline, highly active against common bacterial pathogens in ABSSSI, RTI and UTI appeared first on Outbreak News Today.